SMT reported quarter two FY 2027 revenue of around INR373 crores, up 24.7%, and EBITDA of INR65 crores, up 36.6%, lifting margin to 17.6%. Sironity was commercialized in India, while AVDC 1.5 received CE approval.
SMT · Sahajanand Medical Technologies Limited
Volume · Nov 13
104.67K
Avg daily vol (16 sessions)
339.2K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Investor day
Close535.20 INR
Open538.30 INR
Day489.95–544.05 INR
Available close range378.20–535.20 INR
Avg vol available · 16d339K
Last earningsNov 5, 2026
DataOct 2026–Nov 2026
The closing range uses available history since Oct 23, 2026; less than a full year is stored.
Latest documents
2026
Nov 5
Earnings call
Record Results Drive EBITDA Margin Expansion
Technicals
trend & momentum for long-term holders illustrative — not investment advicePrice context
position in its available closing range
Range low 378.20 INR
Now 535.20 INR · 100%
Range high 535.20 INR
Illustrative technical + ownership context — a signal mix, not investment advice.
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XBOM:SMT | +1.8% | — | — | +16.4% | — |
Exchange listing
- Market
- XBOM
- Ticker
- SMT
- ISIN
- INE356Y01018
- Security
- Ordinary share
- Trading currency
- INR
Company
- Website
- https://www.smtpl.com/
- Investor relations
- https://www.smtpl.com/investor
Other listings of this company
Share classes and depositary receipts can have different prices and dividends.
Recent dividends
No verified dividend payments are available for this listing yet.
Upcoming investor events
No upcoming investor events are listed for this company yet.
Earnings calls
-
Earnings call · Q2 2027 2026-11-05 TranscriptEarnings Call